$0 Co-Pay 
Program
co-pay-caret
Child and caregiver image Child and caregiver image

CUVPOSA (glycopyrrolate) is the first and only FDA-approved treatment indicated to reduce Chronic Severe Drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling (eg, cerebral palsy).1


Liquid formulation: designed with purpose

Liquid formulation icon

Convenient for your patient

Helps ensure that your patient receives the intended dose.*

*Use an accurate dose-measuring cup to get the right dose of CUVPOSA.1

Convenient cup icon

Convenient for your caregiver

No mixing or pill crushing. No more asking your patient to finish their food so they receive the proper dose.

†Give CUVPOSA at least 1 hour before or 2 hours after meals.1

Oral syringe icon

Convenient for you

Easy to titrate based on your patient's needs to deliver an individualized dose.


Study design1

CUVPOSA was evaluated in a multi-center, randomized, double-blind, placebo-controlled, parallel, eight-week study for the control of pathologic drooling in children (Study 1). The study enrolled 38 subjects aged 3-23 years; thirty-six subjects were aged 3-16 years and two patients were greater than 16 years.

The subjects were male or female, weighed at least 13 kg (27 lbs), and had cerebral palsy, mental retardation, or another neurologic condition associated with problem drooling defined as drooling in the absence of treatment so that clothing became damp on most days (approximately five to seven days per week).

Subjects were randomized in a 1:1 fashion to receive CUVPOSA or placebo. Doses of study medication were titrated over a 4-week period to optimal response beginning at 0.02 mg/kg three times a day increasing doses in increments of approximately 0.02 mg/kg three times per day every 5-7 days, not to exceed the lesser of approximately 0.1 mg/kg three times per day or 3 mg three times per day.

Significant reduction in drooling1

CUVPOSA® was tested in a clinical trial. At the end of this study—8 weeks after starting treatment—75% of patients who were given CUVPOSA saw a reduction in drooling. Only 11% of patients who received the placebo saw a reduction after 8 weeks. And patients treated with CUVPOSA also saw some reductions as early as the fourth week of treatment.1

‡In the clinical trial, half the patients, chosen at random, received CUVPOSA; the other half received a placebo (similar-looking and -tasting liquid with no medicine in it). Neither the patients nor the doctors knew who got which until the trial was completed.

75% of patients who were given CUVPOSA® in a clinical study saw a reduction in drooling by week 8.

Measuring the reduction

To measure the amount of drooling before and after treatment, the doctors used the modified Teacher’s Drooling Scale (mTDS). It provides a numerical score based on how often a child drools and how severe it is. The scale goes from 1 to 9. One is the lowest level of drooling; 9 is the highest.1

In this clinical trial, an improvement was defined as at least a 3-point reduction in the drooling scale (eg, the patient started at 7 and ended at 4).

Mean (±2 standard errors) mTDS Scores1

4 week response efficacy chart

Nine-Point mTDS1

  1. Dry: never drools
  2. Mild: only the lips are wet; occasionally
  3. Mild: only the lips are wet; frequently
  4. Moderate: wet on the lips and chin; occasionally
  5. Moderate: wet on the lips and chin; frequently
  6. Severe: drools to the extent that clothing becomes damp; occasionally
  7. Severe: drools to the extent that clothing becomes damp; frequently
  8. Profuse: clothing, hands, tray, and objects become wet; occasionally
  9. Profuse: clothing, hands, tray, and objects become wet; frequently

Safety profile

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a longer, 24 week, open-label study of 137 subjects, the most commonly reported adverse reactions were similar to those seen in the placebo-controlled clinical trial.1


REFERENCE:
  1. CUVPOSA® [package insert]. Raleigh, NC: Merz North America, Inc; 2018.